卵巢癌，由于缺乏有效的诊断方法和治疗方案，其5年生存率仅10%-30%。双微体（DMs）是肿瘤细胞特有的细胞遗传学标记，是肿瘤恶性转变的标志。本课题组前期研究发现了卵巢癌细胞双微体基因组上携带的核糖体蛋白基因RPL22L1，该基因不但在卵巢癌患者组织中特异性高表达，而且敲除该基因会显著降低卵巢癌细胞的恶性表型，是良好的卵巢癌分子诊断和个体化治疗的候选靶点。本项目拟（1）研究RPL22L1基因对卵巢癌细胞周期、增殖、侵袭和迁移等生命活动的影响以及其与p53、MDM2等相关基因的相互作用机制，确认该基因参与卵巢癌发生的功能；（2）通过动物体内实验研究其与化疗药物敏感性的关系，确认该基因结合化疗药物治疗卵巢癌的方案；（3）分析临床卵巢癌患者血液和组织中RPL22L1的变异，确认该基因与患者病理进程及预后相关性。本研究不仅为卵巢癌的诊断提供全新的标靶，还为有效的卵巢癌个体化治疗开创美好前景。

Ovarian Cancer, due to lack effective method of diagnosis and therapy, the five year survival rate is only 10%-30%. Double minutes (DMs) is a specific cytogenetic maker in neoplastic cells,often response for tumor malignancy turning and drug resistent. Recently we obtained composition of DMs in ovarian cancer cell- ribosomal protein gene RPL22L1 by sequencing,which is particular expressed in ovarian carcinoma tissue, and RPL22L1 knockdown will inhibit ovarian cancer cell malignant phenotype significantly, which is a potential favorable maker for molecular diagnosis and invidual therapy. The project will (1)evaluate ovarian cancer cell cycle, proliferation, invasion and migration,also explore the interaction mechanism between RPL22L1, p53 and p53 relative genes to confirm the function of RPL22L1 in tumorigenesis of ovarian cancer; (2)make a study of interaction between RPL22L1 and chemotherapeutics in vitro and in vivo, identify the therapeutic effectiveness of combining gene targeting RPL22L1 with chemotherapy; (3) analyze the RPL22L1 variation in cancer tissue and blood in clinical ovarian cancer patients, confirm the correlation between RPL22L1 and clinical pathology factors and prognosis. The project will not only supply the effective target for ovarian cancer molecular dignosis,but also provide a new view for invidual therapy.